Alfred R. Rudolph

1.1k total citations
15 papers, 869 citations indexed

About

Alfred R. Rudolph is a scholar working on Immunology, Surgery and Oncology. According to data from OpenAlex, Alfred R. Rudolph has authored 15 papers receiving a total of 869 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Surgery and 4 papers in Oncology. Recurrent topics in Alfred R. Rudolph's work include Immune Cell Function and Interaction (3 papers), Immunotherapy and Immune Responses (3 papers) and Virus-based gene therapy research (2 papers). Alfred R. Rudolph is often cited by papers focused on Immune Cell Function and Interaction (3 papers), Immunotherapy and Immune Responses (3 papers) and Virus-based gene therapy research (2 papers). Alfred R. Rudolph collaborates with scholars based in United States. Alfred R. Rudolph's co-authors include Michael S. Mulligan, Peter A. Ward, Scott K. Pruitt, Fred Sanfilippo, Henry C. Marsh, R. Randal Bollinger, Chen‐Hao Yeh, James L. Levin, Bradley H. Collins and Robert L. Comis and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Alfred R. Rudolph

15 papers receiving 842 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfred R. Rudolph United States	14	355	341	144	141	127	15	869
A. D. Crockard United Kingdom	15	422 1.2×	117 0.3×	234 1.6×	128 0.9×	47 0.4×	48	927
Susan K. Anderson United States	18	349 1.0×	236 0.7×	445 3.1×	149 1.1×	65 0.5×	30	1.3k
Yansui Li United States	14	604 1.7×	208 0.6×	259 1.8×	77 0.5×	115 0.9×	18	1.2k
S Aotsuka Japan	22	464 1.3×	80 0.2×	182 1.3×	103 0.7×	55 0.4×	64	1.2k
P. Gjörstrup Sweden	10	293 0.8×	147 0.4×	179 1.2×	187 1.3×	40 0.3×	15	912
M.J. Garlepp Australia	18	397 1.1×	86 0.3×	171 1.2×	126 0.9×	115 0.9×	38	1.2k
Kenji Watabe Japan	21	212 0.6×	234 0.7×	538 3.7×	205 1.5×	66 0.5×	53	1.1k
Nicol Poncina Italy	14	419 1.2×	143 0.4×	382 2.7×	131 0.9×	77 0.6×	16	1.1k
Tamotsu Miyazaki Japan	19	311 0.9×	598 1.8×	424 2.9×	137 1.0×	70 0.6×	88	1.5k
Nicolas Poirier France	23	1.1k 3.0×	249 0.7×	194 1.3×	223 1.6×	129 1.0×	69	1.5k

Countries citing papers authored by Alfred R. Rudolph

Since Specialization

Citations

This map shows the geographic impact of Alfred R. Rudolph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfred R. Rudolph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfred R. Rudolph more than expected).

Fields of papers citing papers by Alfred R. Rudolph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfred R. Rudolph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfred R. Rudolph. The network helps show where Alfred R. Rudolph may publish in the future.

Co-authorship network of co-authors of Alfred R. Rudolph

This figure shows the co-authorship network connecting the top 25 collaborators of Alfred R. Rudolph. A scholar is included among the top collaborators of Alfred R. Rudolph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfred R. Rudolph. Alfred R. Rudolph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Pruitt, Scott K., R. Randal Bollinger, Bradley H. Collins, et al.. (1997). EFFECT OF CONTINUOUS COMPLEMENT INHIBITION USING SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON SURVIVAL OF PIG-TO-PRIMATE CARDIAC XENOGRAFTS1. Transplantation. 63(6). 900–902. 69 indexed citations

Couser, William G., Richard J. Johnson, Bessie A. Young, et al.. (1995). The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis.. Journal of the American Society of Nephrology. 5(11). 1888–1894. 81 indexed citations

Pruitt, Scott K., Allan D. Kirk, R. Randal Bollinger, et al.. (1994). THE EFFECT OF SOLUBLE COMPLEMENT RECEPTOR TYPE 1 ON HYPERACUTE REJECTION OF PORCINE XENOGRAFTS. Transplantation. 57(3). 363–370. 199 indexed citations

Gillinov, A. Marc, Patrick A. DeValeria, Jerry A. Winkelstein, et al.. (1993). Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. The Annals of Thoracic Surgery. 55(3). 619–624. 65 indexed citations

Flaherty, Lawrence E., Bruce G. Redman, Silvana Martino, et al.. (1993). A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer. 71(11). 3520–3525. 57 indexed citations

Mulligan, Michael S., Jeffrey S. Warren, C. Wayne Smith, et al.. (1992). Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine. The Journal of Immunology. 148(10). 3086–3092. 77 indexed citations

Mulligan, Michael S., et al.. (1992). Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury. The Journal of Immunology. 148(5). 1479–1485. 134 indexed citations

Zamkoff, Kenneth W., et al.. (1992). A Phase I Trial of Recombinant Human Macrophage Colony-Stimulating Factor by Rapid Intravenous Infusion in Patients with Refractory Malignancy. Journal of Immunotherapy. 11(2). 103–110. 17 indexed citations

Konrad, Michael, Edward C. Bradley, Gary E. Goodman, et al.. (1992). Interferon-γ Induced by Administration of Recombinant Interleukin-2 to Patients with Cancer. Journal of Immunotherapy. 12(1). 55–63. 4 indexed citations

10.

Krigel, Robert L., Kristin Padavic‐Shaller, Alfred R. Rudolph, et al.. (1990). Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.. Journal of Clinical Oncology. 8(3). 460–467. 36 indexed citations

11.

Scuderi, Philip, et al.. (1989). A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy. 1(3). 207–214. 16 indexed citations

12.

Krigel, Robert L., Kristin Padavic‐Shaller, Alfred R. Rudolph, et al.. (1988). A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.. PubMed. 48(13). 3875–81. 43 indexed citations

13.

Dollbaum, Charles M, Abla A. Creasey, Shanaz H. Dairkee, et al.. (1988). Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin.. Proceedings of the National Academy of Sciences. 85(13). 4740–4744. 29 indexed citations

14.

Graziano, Stephen L., et al.. (1987). Mixed germ-cell tumor of the pineal region. Journal of neurosurgery. 66(2). 300–304. 25 indexed citations

15.

Comis, Robert L., Brian F. Issell, Kenneth A. Pittman, et al.. (1982). A phase I and clinical pharmacology study of intravenously administered carminomycin in cancer patients in the United States.. PubMed. 42(7). 2944–8. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact